Epidermal growth factor (EGF) reproduces many of the effects of estrogen on the murine female reproductive tract and may partially mediate estroged-induced growth and differentiation. This study was performed to investigate the mechanism by which EGF elicits estrogen-like actions in the whole animal. EGF was ad tered to adult ovariectomized mice by slow release pellets implanted under the kidney capsule. The induction ofuterine DNA synthesis and phosphatidylinositol lipid turnover by EGF or admintation of diethylstilbestrol (5 pg/kg), a potent estrogen, was attenuated by the estrogen receptor antagonist ICI 164,384. Furthermore, EGF mimicked the effects of estrogen on enhanced nuclear localization of the estrogen receptor and the formation of a unique form of the estrogen receptor found exclusively in the nucleus. These results suggest that EGF may induce effects similar to those of estrogen in the mouse uterus by an interaction between the EGF signaling pathway and the classical estrogen receptor. The demonstration of cross-talk between polypeptide growth factors and steroid hormone receptors may be of importance to our understanding of the regulation of normal growth and differentiation as well as the mechanisms of transmission of extracellular mitogen signals to the nucleus.
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It has been proposed that polypeptide growth factors may act as autocrine or paracrine mediators of estrogen-induced mitogenesis (1, 2) . The observations that estrogen induces mRNA and protein for both epidermal growth factor (EGF) (3, 4) and its receptor (5) (6) (7) in rodent uterus are consistent with this hypothesis and implicate a role for the EGF receptor signaling pathway in steroid hormone regulation of uterine tract growth. Furthermore, exogenous EGF administration to adult ovariectomized mice mimics the effects of estrogen on proliferation and differentiation in the murine female reproductive tract (8) . EGF-induced mitogenesis in this model is not affected by adrenalectomy or hypophysectomy, which indicates that adrenal or pituitary hormones do not mediate the effects of EGF. In addition, the fact that an EGF-specific antibody administered prior to estradiol partially blocks estrogen-induced uterine epithelial cell proliferation (8) suggests that production of EGF may be necessary for estrogen-induced responses.
Presently, the mechanism by which the actions of estrogens and EGF converge is unknown. This study addresses the intriguing possibility that some of the physiological actions of EGF, an extracellular ligand, may be mediated through a nuclear steroid hormone receptor, namely, the estrogen receptor (ER). Two recent reports by Power et al. (9, 10) support such a hypothesis. These studies demonstrated that dopamine, an extracellular ligand, was able to stimulate transcriptional enhancement by three members of the steroid receptor superfamily [the progesterone receptor (PR), ER, and COUP (chicken ovalbumin upstream promoter) transcriptional enhancer], which were transfected into CV1 monkey kidney cells. Furthermore, in MCF-7 human breast cancer cells, the ability of antiestrogens to suppress the induction of mitogenesis and elevation of PR levels (classical estrogen-inducible responses) by peptide growth factors (11, 12) suggests a role for ERs in the actions of extracellular mitogens.
In this investigation, we have examined the in vivo effect of a "pure" antiestrogen, ICI 164,384 (ICI) (13), on estrogenand EGF-inducible responses in the mouse uterus. In addition to EGF-induced uterine DNA synthesis, the effect of EGF on phosphatidylinositol (PI) lipid metabolism was assessed. Activation of uterine PI lipid turnover is one of the earliest and most persistent effects ofestrogen administration and this effect is mediated by the ER (14, 15) . The metabolic products of PI lipids are mediators of signal transduction and cellular proliferation for many hormones and polypeptide growth factors, including EGF, which is thought to enhance metabolism of PI lipids by phosphorylation and activation of phospholipase Cy (16, 17) . This signaling pathway, therefore, is a potentially important point of convergence of the actions of EGF and estrogen in the uterus.
We (8) . For biochemical analysis, tissue was homogenized in TEGM buffer [10 mM Tris HCl/ 1.5 mM EDTA/10% (vol/vol) glycerol/3 mM MgCl2, pH 7.6] and the nuclear pellet was resuspended in TEGM buffer containing 2.2 M NaCl. The amount of trichloroacetic acidprecipitable radioactivity per ,ug of DNA was assessed as described (15) . Treatment of tissue for histological examination was performed as described (8) . Uterine tissue was fixed in Bouin's fixation solution and embedded in paraffin for sectioning. The number of labeled and unlabeled luminal epithelial cells along the basement membrane was quantitated in sections that had been dipped in Kodak photographic emulsion (Eastman Kodak), developed after 2 weeks exposure, and stained with hematoxylin and eosin. Quantitation was performed on six to eight uteri per group. Data are presented as the mean of the percentage of labeled nuclei per unit basement membrane.
Biochemical Analyses of the ER. The [3H]estradiol binding assay was performed as described (18) with modifications (19) . Uterine tissue was homogenized in ice-cold TEGM buffer and the nuclear pellet was washed twice in this buffer.
[3H]Estradiol binding was measured in both the nuclear and cytosolic fractions. Data The gel-retardation assay was performed as described (22) . Briefly, uteri were homogenized in TGM buffer (10 mM TrisHCl/10% glycerol/3 mM MgCl2, pH 7.6) containing protease inhibitors (23 [12] [13] [14] [15] [16] .
The ability of an ER antagonist to block the cellular actions of EGF in the whole animal prompted an investigation of the effects of EGF on biochemical characteristics of the ER. Estrogen treatment rapidly enhances ER affinity for chromatin so that the ER is retained in the nuclear fraction after tissue homogenization. This phenomenon can be quantitated by a [3H]estradiol binding assay (18, 19) . As shown in Fig. 3 , significant augmentation of nuclear ER levels was observed 1.5 h after EGF pellet implantation or DES treatment. Enhanced nuclear retention of ER after EGF treatment was further corroborated by the immunodetection of greater levels of ER protein, which migrated at -65 kDa in uterine nuclear extracts as detected with the ER monoclonal antibody H-222 (Fig. 4A) . The protein that migrated at :54 kDa is a proteolytic fragment of the ER (23). Since a corresponding decrease in cytosolic ERs was observed by both receptor binding and Western blot, an actual redistribution of receptors probably occurs rather than simply a change in the amount of ER (data not shown).
Since interaction of the ER with the ERE is a prerequisite for transcriptional activation, the nuclear ER from EGFtreated mice was tested for this ability to determine if the Fig. 3 . Nuclear proteins were extracted from uterus, precipitated with ammonium sulfate, and then in preparation for the gel-retardation assay, were subjected to SDS/PAGE on a 32-cm Tall Boy gel (Hoeffer Scientific) and transferred to nitrocellulose, and the ER was detected with anti-ER monoclonal antibody H-222. Lanes: 1, placebo pellet; 2, EGF pellet; 3, DES. The two ER bands that form the doublet are marked by arrows. The lowest molecular mass band observed in both placebo and EGF samples is believed to be a proteolytic fragment of the ER (23) . The asterisk indicates the position of the 69-kDa molecular mass marker.
with the ERE was assessed using a vitellogenin A2 ERE in a gel-retardation assay. The results shown in Fig. 4B This laboratory has demonstrated (19) that in vivo estrogen treatment induces heterogenous nuclear forms of the 65-and 66.5-kDa ER in uterine nuclear extracts. This type of phenomenon has also been observed with chicken oviduct PR after progesterone treatment (24) . Phosphorylation of both ER forms is stimulated by estrogen treatment but this effect is more prominent for the higher molecular weight form found exclusively in the nuclear fraction (20) . Similar to the effect of estrogen, EGF treatment induced the appearance of the 66.5-kDa nuclear form of the ER (Fig. 5, lane 2) . A typical uterine nuclear extract from DES-treated mice is shown in Fig. 5 (27) . This antagonist also causes a 60o decrease in ER level in MCF-7 breast cancer cells (28) . Thus, the mechanism of antagonism of the biological effects of both DES It is intriguing that the biochemical attributes of the ER after estrogen or EGF treatment are similar. It is thought that the ER binds more tightly to chromatin after in vivo steroid treatment and that a more highly phosphorylated form of ER is produced that is found only in the nuclear fraction (20) . We have shown that EGF administered to the whole animal mimics the effects of estrogen on these biochemical characteristics. The ER seems to behave as if it is occupied by ligand, but to our knowledge serum estradiol is undetectable after EGF treatment of ovariectomized mice (8) . Furthermore, EGF-induced uterine DNA synthesis occurred in mice that were hypophysectomized, adrenalectomized, and ovariectomized (8) . In addition, the aforementioned cell culture results obtained in the absence of steroids that have been reported by several other groups (9) (10) (11) (12) are suggestive of interactions between extracellular ligands and steroid receptors and support our in vivo observations. It remains to be proven, however, whether EGF can actually induce transcriptional activation through an ERE in the absence of estrogen. The studies by Power et al. (9, 10 ) that demonstrated that dopamine could activate the ER, PR, and COUP transcription factor in transfected CV1 cells support such a possibility. PR activation by dopamine, but not progesterone, was dependent on a specific serine residue in the PR that is phosphorylated after treatment with dopamine, an activator of adenylate cyclase. In addition, in the absence of progesterone, the PR could activate transcription after cells were treated with agents that enhance phosphorylation (presumably of the PR or other proteins involved in transcription) (29) . These observations support a role for phosphorylation in the interaction of the extracellular ligand and the nuclear receptor. Certainly, EGF induces phosphorylation of various second messengers, thereby activating their signaling cascades (14, 15, 30, 31) . One hypothesis to explain the results presented here is that EGF activates its receptor tyrosine kinase, which, in turn, influences key signaling intermediates that interact with the ER in the nucleus.
In summary, these results demonstrate that the action of a polypeptide growth factor may modulate a classical steroid hormone receptor, which adds another dimension to the autocrine loop model. Estrogens may upregulate autocrine or paracrine polypeptide growth factor signaling pathways whose effects, in turn, may be partially mediated by the ER itself. Our results in the whole animal suggest that cross-talk between growth factors and steroid hormone receptors may be relevant to the regulation of normal growth and differentiation in the female reproductive tract. Thus, the earlier hypothesis that steroid receptor transcriptional enhancers are activated only in the presence of steroid ligand may not be totally valid. Finally, the mechanism suggested in this report may be of global importance in understanding the physiological mechanisms of extracellular mitogen signaling interactions with transcription factors in the nucleus. 
